Virtual Library
Start Your Search
Inmaculada Ramos
Author of
-
+
P38 - Pathology - Pathology/Staging (ID 108)
- Event: WCLC 2020
- Type: Posters
- Track: Pathology, Molecular Pathology and Diagnostic Biomarkers
- Presentations: 1
- Moderators:
- Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall
-
+
P38.19 - Lung Cancer in Young Adults: A Two-Center, Retrospective Study of the Clinical and Pathological Characteristics (ID 3259)
00:00 - 00:00 | Author(s): Inmaculada Ramos
- Abstract
Introduction
Lung cancer is the main cause of death due to cancer worldwide, representing nearly 25% of the total deaths by cancer. It is mainly diagnosed in people around 70 years-old, counting just a few cases under 40. The objective of this study is to analize the characteristics of patients under 40 diagnosed of lung cancer, and describe the prognostic variables for a better understanding of this disease in this specific setting.
Methods
A retrospective, descriptive study of 47 patients between 15-40 years old diagnosed of lung cancer in Hospital Universitario Virgen de la Victoria and Regional Universitario de Málaga, from January 2000 to May 2020 was carried out. Family and personal background, histology, stage, and localization of the tumor was analyzed, as well as detection of molecular mutations and treatments given during the course of the disease. A frequency analysis of qualitative and quantitative variables was made. The survival curves were calculated by Kaplan Meier, with a level of significance of p<0,05.
Results
Median age was 34 years-old (range 15-40), of which 51% were women (n=24), without previous oncological family history in a 76,6% (n=36), and smoking history in a 55% (n=18). Diagnostic symptoms were mainly pain (28,2%), cough (17,9%) and dyspnea (10,3%), and regarding histology, 38% were adenocarcinomas and 21,3% typical carcinoids. As reported in previous studies, around 79% (n=36) were advanced stages, TNM III-IV. Mutation-gene analysis was made in 40% (n=19) of the patients, 12,7% being positive for EGFR (n=6) and 4,3% for ALK (n=2), all of which where treated with genotype-directed treatment.
Median-overall survival was 102 months (range 22-182), being just 17 months in the subgroup of non-carcinoid tumors, with a progression-free survival of 6 months.
Conclusion
Lung cancer in young adults is a non-frequent pathology that represents an interesting challenge for the Oncologist. Recognizing physiological and molecular characteristics will enable a better clinical and therapeutic approach.
-
+
P75 - Immunotherapy (Phase II/III Trials) - Misc. Topics (ID 248)
- Event: WCLC 2020
- Type: Posters
- Track: Immunotherapy (Phase II/III Trials)
- Presentations: 1
- Moderators:
- Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall
-
+
P75.16 - Real-World Data from a Spanish Institution (ID 1179)
00:00 - 00:00 | Presenting Author(s): Inmaculada Ramos
- Abstract
Introduction
The introduction of immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC) has resulted in a new era of treatment options that have substantially improved efficacy and tolerability when compared to chemotherapy. The validation of evidence coming from landmark clinical trials with real-world data, as well as the search for predictive biomarkers for checkpoint inhibitor-based immunotherapy, comprise the main aims of this study.
Methods
Retrospective cohort study analysing 230 patients with advanced non-small-cell lung cancer (NSCLC) treated with immunotherapy in the Integral Oncology Clinical Management Unit of Málaga (Spain). The primary endpoints were overall survival (OS) and progression-free survival (PFS).
Results
Among 230 patients, the demographics were: 170 (73.9%) men and 60 (26.1%) women. Median age of 66 years. 106 (46.1%) current smokers, 100 (43.5%) former smokers and 18 (7.8%) had never smoked. 88 (38.3%) squamous NSCLC, 141 (61.4%) non-squamous NSCLC and 1 (0.4%) adenosquamous NSCLC. The safety profile was in accordance with literature data.
The median overall survival was 10 months (95% CI 8.185-11.815) and the median progression-free survival was 3 months (95% CI 2.532-3.468). Statistically significant results were found in the median OS of the following independent variables: ECOG performance status at the beginning of the immunotherapy; number of line of the immunotherapy; use of immunotherapy in patients with severe smoking history (>39 pack-years); antibiotic treatment administration within one month before or after the beginning of the immunotherapy, and use of radiotherapy at any time of the clinical course of the disease.
Conclusion
The present data reinforce the evidence coming from landmark clinical trials and support the early use of immunotherapy. Regarding the predictive biomarkers for checkpoint inhibitor-based immunotherapy, the outcomes are concordant with present literature data. All this real-world evidence contributes, thus, to sustain the inclusion in therapeutic protocols and payer decision making.
